EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

Preclinical and clinical evaluation of LY3451838, a PACAP-neutralizing monoclonal antibody, in randomized, double-blind, placebo-controlled phase 1 and phase 2 studies involving healthy adults and adults with treatment-resistant migraine

Michael P Johnson iD, Judith Krikke-Workel, Chetan N Patel, S Michelle Morin, P Kellie Turner, Kristie A Clark, David Donley, Yan Jin, Kirk W Johnson, Maurice Vincent, John R Stille, Lisa M Broad und 1 weitere

Cephalalgia · 2025

DOI: 10.1177/03331024251368757 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cephalalgia, 2025. Verfasst von Michael P Johnson und 12 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, Indianapolis, IN, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Pituitary Adenylate Cyclase-Activating Polypeptide, Antibodies, Monoclonal, Antibodies, Neutralizing. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: This study is sponsored by Eli Lilly and Company..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

LY3451838 is a monoclonal antibody against pituitary adenylate cyclase-activating peptide (PACAP), a target in migraine research. The present study aimed to evaluate LY3451838 as a preventive treatment for participants with treatment-resistant migraine.

Methods

Following preclinical assessment of LY3451838, including pharmacokinetic and pharmacodynamic studies, safety was evaluated in a phase 1 study of LY3451838 (n = 33) versus placebo (n = 13) in healthy participants. A phase 2 trial was carried out in treatment-resistant participants with chronic migraine (CM) (n = 16) or episodic migraine (EM) (n = 22). In phase 2, participants received a single intravenous (IV) dose of 1500 mg LY3451838 (n = 19) or placebo (n = 19) and completed ePRO daily diaries. Participants were followed for safety for 140 days.

Results

In phase 2, at one-month post-dose, patients who had received a single IV dose of LY3451838 exhibited greater changes from baseline than placebo in mean monthly migraine headache days in both the CM and EM subgroups (CM: −4.7 days vs. −3.0 days; EM: −1.7 days vs. −1.2 days), but the treatment contrast was not statistically significant in either subgroup. Similar non-significant results were seen at the three-month time point. The percentage of participants reporting treatment-emergent adverse events was similar for LY3451838 and placebo, with one serious adverse event of B-cell lymphoma in an LY3451838-treated participant that led to study discontinuation.

Conclusions

LY3451838 did not demonstrate superior efficacy over placebo in patients with treatment-resistant CM or EM. However, the difference observed between LY3451838 and placebo among CM patients is similar to the statistically significant difference reported in the recent HOPE trial, which primarily consisted of CM patients. Further clinical research with larger sample sizes is needed to inform on the utility of blocking PACAP in various migraine populations. Trial Registration ClinicalTrials.gov: NCT03692949 (phase 1); NCT04498910 (phase 2).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersPituitary Adenylate Cyclase-Activating PolypeptideAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, Monoclonal, HumanizedHumansDouble-Blind MethodAdultMaleFemaleMiddle AgedYoung AdultTreatment OutcomeDrug Evaluation, Preclinical

Stichwörter der Autor:innen

PACAPchronic migraineepisodic migrainephase 1phase 2treatment-resistant migraine

Substanzen

Pituitary Adenylate Cyclase-Activating PolypeptideAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Eli Lilly and Company, Indianapolis, IN, USA.
  • EMB Statistical Solutions, LLC, Overland Park, KS, USA.
  • Bio Behavioral Health, Toms River, NJ, USA.

ORCID-Profile: Michael P Johnson

Förderung

  • This study is sponsored by Eli Lilly and Company.

Zitieren

APA

Johnson, M. P., Krikke-Workel, J., Patel, C. N., Morin, S. M., Turner, P. K., Clark, K. A., Donley, D., Jin, Y., Johnson, K. W., Vincent, M., Stille, J. R., Broad, L. M., & Patel, A. (2025). Preclinical and clinical evaluation of LY3451838, a PACAP-neutralizing monoclonal antibody, in randomized, double-blind, placebo-controlled phase 1 and phase 2 studies involving healthy adults and adults with treatment-resistant migraine. Cephalalgia. https://doi.org/10.1177/03331024251368757

Vancouver

Johnson MP, Krikke-Workel J, Patel CN, Morin SM, Turner PK, Clark KA, et al. Preclinical and clinical evaluation of LY3451838, a PACAP-neutralizing monoclonal antibody, in randomized, double-blind, placebo-controlled phase 1 and phase 2 studies involving healthy adults and adults with treatment-resistant migraine. Cephalalgia. 2025. doi:10.1177/03331024251368757

BibTeX
@article{Johnson2025,
  author = {Johnson, Michael P and Krikke-Workel, Judith and Patel, Chetan N and Morin, S Michelle and Turner, P Kellie and Clark, Kristie A and Donley, David and Jin, Yan and Johnson, Kirk W and Vincent, Maurice and Stille, John R and Broad, Lisa M and Patel, Ashok},
  title = {Preclinical and clinical evaluation of LY3451838, a PACAP-neutralizing monoclonal antibody, in randomized, double-blind, placebo-controlled phase 1 and phase 2 studies involving healthy adults and adults with treatment-resistant migraine},
  journal = {Cephalalgia},
  year = {2025},
  doi = {10.1177/03331024251368757}
}
Kostenlos starten →